
A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug …

Roche has revealed further data from its Phase 3, IMpower150 study, which showed that a combination of Tecentriq and Avastin, …

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …

A team of researchers at Oxford’s John Radcliffe Hospital have unveiled a new artificial intelligence system which they claim could …

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …

AstraZeneca and its partner Hutchison China MedTech, also known as Chi-Med, have announced positive data for savolitinib in combination with …

Through the use of molecular screening, functional proteomics and computer-based modelling, researchers from the Moffitt Cancer Center have been working …

AstraZeneca has announced that its targeted therapy, Tagrisso (osimertinib), has been awarded Breakthrough Therapy Designation by the FDA for the …

It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …

Researchers at Ohio State University have discovered that, as well as forming a key part of treatment strategies to fight …

According to a new report commissioned by the ABPI, the UK is continuing to fall behind in the diagnosis and …

AstraZeneca has been boosted by the news that its drug, Tagrisso, has become its first drug to be approved under …

According to a new report from Technavio, the global lung cancer therapeutics market is projected to grow at more than …